IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.
Animals
Carcinoma, Renal Cell
/ genetics
Cell Line, Tumor
Cell Proliferation
/ physiology
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Interleukin-8
/ genetics
Kidney Neoplasms
/ genetics
Lung Neoplasms
/ genetics
Mice
Neoplastic Stem Cells
/ pathology
Receptors, Interleukin-8A
/ genetics
Receptors, Interleukin-8B
/ antagonists & inhibitors
CXCL8
CXCR1
IL-8
metastasis
renal cancer
stem cells
xenografts
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
27
09
2018
revised:
25
02
2019
accepted:
13
03
2019
pubmed:
19
3
2019
medline:
9
4
2020
entrez:
19
3
2019
Statut:
ppublish
Résumé
Recent studies suggest that clear cell renal cell carcinoma (ccRCC) possesses a rare population of cancer stem cells (CSCs) that might contribute to tumor heterogeneity, metastasis and therapeutic resistance. Nevertheless, their relevance for renal cancer is still unclear. In this study, we successfully isolated CSCs from established human ccRCC cell lines. CSCs displayed high expression of the chemokine IL-8 and its receptor CXCR1. While recombinant IL-8 significantly increased CSC number and properties in vitro, CXCR1 inhibition using an anti-CXCR1 antibody or repertaxin significantly reduced these features. After injection into immune-deficient mice, CSCs formed primary tumors that metastasized to the lung and liver. All xenografted tumors in mice expressed high levels of IL-8 and CXCR1. Furthermore, IL-8/CXCR1 expression significantly correlated with decreased overall survival in ccRCC patients. These results suggest that the IL-8/CXCR1 phenotype is associated with CSC-like properties in renal cancer. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Identifiants
pubmed: 30883740
doi: 10.1002/path.5267
pmc: PMC6618115
doi:
Substances chimiques
Interleukin-8
0
Receptors, Interleukin-8A
0
Receptors, Interleukin-8B
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-389Informations de copyright
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Références
Am J Pathol. 1999 Apr;154(4):981-6
pubmed: 10233835
Biochim Biophys Acta. 2003 Sep 30;1606(1-3):137-46
pubmed: 14507434
Br J Cancer. 2004 Nov 29;91(11):1970-6
pubmed: 15545974
Carcinogenesis. 2007 Mar;28(3):529-36
pubmed: 16920734
Cancer Res. 2007 May 1;67(9):4010-5
pubmed: 17483311
Annu Rev Pathol. 2007;2:145-73
pubmed: 18039096
J Pathol. 2008 Mar;214(4):464-71
pubmed: 18189328
J Clin Invest. 2008 Jun;118(6):2111-20
pubmed: 18497886
FASEB J. 2008 Oct;22(10):3696-705
pubmed: 18614581
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Cell. 2009 Sep 4;138(5):822-9
pubmed: 19737509
Cell Cycle. 2009 Oct 15;8(20):3274-84
pubmed: 19770585
J Clin Invest. 2010 Feb;120(2):485-97
pubmed: 20051626
PLoS One. 2010 Apr 21;5(4):e10277
pubmed: 20422001
Int J Nephrol. 2011;2011:286985
pubmed: 21647312
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
Nat Rev Cancer. 2012 Jan 12;12(2):133-43
pubmed: 22237392
Br J Cancer. 2012 May 22;106(11):1833-41
pubmed: 22617157
Semin Cancer Biol. 2013 Feb;23(1):56-61
pubmed: 22766133
BMC Cancer. 2012 Jul 23;12:310
pubmed: 22824167
Oncol Lett. 2011 Nov;2(6):1095-1100
pubmed: 22848273
Nat Biotechnol. 2012 Sep;30(9):858-67
pubmed: 22902532
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Clin Cancer Res. 2013 Sep 15;19(18):5218-26
pubmed: 23881929
Am J Surg Pathol. 2013 Oct;37(10):1463-8
pubmed: 24025518
PLoS One. 2013 Oct 08;8(10):e75463
pubmed: 24116047
Eur J Cancer. 2014 Jan;50(2):341-50
pubmed: 24161763
Cancer Res. 2014 Feb 1;74(3):873-83
pubmed: 24335961
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Sci Rep. 2014 Aug 01;4:5911
pubmed: 25081383
Cancer Res. 2014 Sep 1;74(17):4671-5
pubmed: 25136075
Clin Cancer Res. 2015 Feb 15;21(4):916-24
pubmed: 25501128
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Clin Cancer Res. 2015 Feb 15;21(4):889-98
pubmed: 25691774
Nat Rev Drug Discov. 2015 Mar;14(3):165
pubmed: 25722238
Oncotarget. 2015 Apr 30;6(12):10415-31
pubmed: 25871388
Stem Cell Rev. 2015 Dec;11(6):919-43
pubmed: 26210994
Tumour Biol. 2016 Apr;37(4):4523-9
pubmed: 26503211
J Exp Clin Cancer Res. 2017 Mar 9;36(1):41
pubmed: 28279221
Cancer Res. 2017 May 15;77(10):2585-2593
pubmed: 28364001
Oncotarget. 2017 May 9;8(19):31977-31992
pubmed: 28404888
Oncoimmunology. 2017 Aug 8;6(11):e1359450
pubmed: 29147624
J Pathol Clin Res. 2018 Jan 17;4(1):3-18
pubmed: 29416873